Back to top
more

Stryker (SYK)

(Delayed Data from NYSE)

$307.80 USD

307.80
3,427,831

+6.66 (2.21%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $307.00 -0.80 (-0.26%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 29% (175 out of 247)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

NuVasive (NUVA) to Expand San Diego Global Headquarters

by Zacks Equity Research

Apart from introducing sophisticated features at the facility, NuVasive (NUVA) plans to open an innovation center of excellence at the San Diego global headquarters.

    Zacks Equity Research

    Stryker Recalls Sage Unit Products, Guidance Takes a Hit

    by Zacks Equity Research

    Added to the voluntary recall, Stryker (SYK) also placed a temporary hold on certain cloth-based products. Share price of Stryker declined massively following the news.

      Mark Vickery headshot

      Top Stock Reports for Duke Energy, Stryker & Sanofi

      by Mark Vickery

      Today's Research Daily features new research reports on 16 major stocks, including Duke Energy (DUK), Stryker (SYK) and Sanofi (SNY).

        Zacks Equity Research

        Ecolab Sales Solid Amid Escalating Delivered Product Costs

        by Zacks Equity Research

        Ecolab's (ECL) strong sales growth will continue to be aided by new business gains, better pricing and product innovation. However, higher delivered product costs remain a concern.

          Zacks Equity Research

          Bruker Launches D8 VENTURE BIOTOOLS for Home Laboratory

          by Zacks Equity Research

          Bruker's (BRKR) D8 VENTURE BIOTOOLS for laboratory macromolecular crystallography has some latest features in terms of source, detector and sample handling technology.

            Zacks Equity Research

            PAREXEL Ties Up With Osaka International Cancer Institute

            by Zacks Equity Research

            We believe tie-ups like these will help PAREXEL (PRXL) drive its top and bottom line. The company also has a competitive edge in the Asia-Pacific markets.

              Zacks Equity Research

              Here's Why Investors Should Buy Amedisys (AMED) Right Now

              by Zacks Equity Research

              Strength in Hospice and Personal Care businesses offset the weakness in Amedisys' (AMED) Home Health Medicare business.

                Zacks Equity Research

                Exactech (EXAC) Truliant Knee System Receives IDEA Award

                by Zacks Equity Research

                Exactech (EXAC) has been leveraging on its Knee business. The Truliant Knee System is a notable platform in the Knee space, which offers an advanced approach to total knee replacement surgeries.

                  Zacks Equity Research

                  Omnicell (OMCL) Gains on Product Launches, Competition Rife

                  by Zacks Equity Research

                  Omnicell (OMCL) launches AcuDose software on XT hardware which allows Aesynt customers to fully benefit from XT. The company also launches XT Series Automated Supply Dispensing system.

                    Zacks Equity Research

                    Align Technology's Invisalign Sales Strong Amid Margin Woes

                    by Zacks Equity Research

                    Align Technology's (ALGN) huge InvisAlign prospects in North America and international regions render optimism. However, escalating costs and expenses put pressure on the company's margins.